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SUMMARY
Introduction Isolated adrenal metastases of invasive ductal breast carcinoma are extremely rare. We 
report a case with isolated left adrenal metastases, verified three years after diagnosed breast carcinoma.
Case Outline A 58-year-old female patient with a right breast tumor, clinically staged as IIIA (T2N2M0) 
started neoadjuvant anthracycline chemotherapy after biopsy which revealed invasive ductal breast 
carcinoma. Immunohistochemical findings of tumor biopsy showed hormonal steroid receptors for 
estrogen and progesterone negative, and human epidermal growth factor receptor 2 (HER2) positive. 
After 4 cycles of chemotherapy and partial tumor regression the patient underwent radical mastectomy. 
Definite histopathological analysis confirmed the diagnosis of invasive ductal carcinoma. The patient 
continued treatment with adjuvant chemotherapy to cumulative dose of anthracyclines, postoperative 
radiotherapy and adjuvant trastuzumab for one year. Three years later abdominal computerized 
tomography showed tumor in the left adrenal gland as the only metastatic site. Left adrenalectomy 
was performed and histopathological finding confirmed breast cancer metastases. Postoperatively, 
the patient received 6 cycles of docetaxel with trastuzumab and continued trastuzumab until disease 
progression. One year after left adrenalectomy control abdominal computerized tomography showed a 
right adrenal tumor with retroperitoneal lymphadenopathy. Treatment with capecitabine was continued 
for one year, but eventually she developed brain metastasis causing lethal outcome.
Conclusion In order to better understand metastatic pathways of invasive ductal breast carcinoma, 
publications of individual patient cases diagnosed with rare metastatic sites should be encouraged. 
This might improve our understanding of metastatic behavior of breast cancer and stimulate further 
clinical research.
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INTRODUCTION
Isolated adrenal metastases originating from 
invasive ductal carcinoma (IDC) of the breast 
are extremely rare. On the other side, metastas-
es in adrenal glands are very frequent autopsy 
findings and in most cases they originate from 
lung, renal and gastrointestinal cancers [1, 2].
The most frequent type of invasive breast 
carcinoma is IDC with frequency of 70 to 85% 
of all breast cancer patients [3, 4]. Clinical 
and pathological findings confirm that IDC 
is mostly associated with lung, liver, bone 
and brain metastases and rarely affects adre-
nal glands, while invasive lobular carcinoma 
(ILC) has a high potential of spreading into the 
gastrointestinal system, gynecological organs, 
peritoneal and retroperitoneal structures [5, 
6]. Generally, adrenal gland metastases com-
ing from breast cancer are characteristic of ILC 
and they are frequently associated with multi-
ple endocrine organs metastases [7]. Adrenal 
metastases, especially isolated metastases, com-
ing from IDC are less often. So far, only one 
case of isolated adrenal metastasis from IDC 
with immunohistochemical (IHC) profile, es-
trogen receptor (ER) negative, progesterone 
receptor (PR) negative and human epidermal 
growth factor receptor 2 (HER2) positive is 
described and published in literature by Liu et 
al. [8] in 2010.
It has been shown that adrenal gland metas-
tases are the indicator of an advanced disease 
and are usually accompanied multiple organ 
metastases involvement [6]. Adrenal metas-
tases in the majority of cases are asymptomatic 
and could be detected predominately on au-
topsy [2]. Nowadays, due to more sophisticated 
imaging procedures used in a routine follow-
up, they are discovered more often. Available 
studies with other solid tumors with isolated 
adrenal metastases have shown that adrenal-
ectomy has significant influence on prolonged 
survival [1, 2, 7, 9]. Due to its rare occurrence, 
the recommendations for optimal treatment 
of adrenal metastases originating from breast 
carcinoma are still missing.
CASE REPORT
We present a clinical case of a 58-year-old fe-
male patient with a lump in her right breast. 
There was no family history of breast or ovar-
ian cancer in primary relatives. Clinical exami-
nation revealed a right breast mass, clinically   
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staged as IIIA (T2N2M0) according to the UICC TNM 
classification. Mammography demonstrated a 50×40 mm 
mass with associated microcalcifications. Excisional bi-
opsy confirmed infiltrative ductal carcinoma, Nottingham 
histological grade (HG) 2 and nuclear grade (NG) 2. IHC 
findings revealed a tumor with ER negative, PR negative, 
HER2 positive 3+ (the percentage of cells with complete 
intensive membrane staining was 100) receptor staining. 
The patient was started on treatment at the Institute for 
Oncology and Radiology of Serbia in July 2007 with neo-
adjuvant FAC chemotherapy (5-fluorouracil 500 mg/m2 
day 1, doxorubicin 50 mg/m2 day 1, cyclophosphamide 
500 mg/m2 day 1, every three weeks). After four cycles of 
chemotherapy, a partial response, i.e. 50% of reduction 
in size for both breast tumor and axillary lymph nodes 
was detected and radical mastectomy was performed in 
October 2007.
Definite histopathology (HP) analysis of tumor after 
radical mastectomy confirmed IDC, HG2, NG2, with 
maximal tumor diameter of 25 mm, and one positive 
axillary lymph node out of 16 examined. She was post-
menopausal for the period of three years. As she had no 
other comorbidities and her performance status was 0, we 
continued treatment with 4 cycles of adjuvant FAC chemo-
therapy, postoperative radiotherapy of the right chest wall 
(42.5 Gy in 16 fractions) and adjuvant trastuzumab (first 
dose 8 mg/kg, followed by 6 mg/kg every three weeks) for 
the period of one year after which she went on regular 
checkups.
Three years after diagnosed primary breast cancer at 
her regular check-ups, abdominal ultrasound showed en-
larged left adrenal gland, in diameter of 49×48 mm. Tumor 
marker CA 15-3 was elevated up to 205.7 (normal range 
0.0–25.0 U/ml). Abdominal computerized tomography 
(CT) confirmed the enlarged left adrenal gland with the 
tumor mass of 48×47.6 mm in diameter. Additional di-
agnostic work-up, CT scan of the chest and bone, have 
confirmed that metastasis in the left adrenal gland was 
the only pathological finding. Laboratory tests and hor-
monal status examination excluded the primary disease 
of adrenal gland. The basal cortisol was within the normal 
range and dexamethason (1 mg) suppression was normal. 
Also, the level of catecholamines was normal. Electrolyte 
balance was within the range of normal values. The patient 
was asymptomatic and fully active with performance sta-
tus of 0. She was obese and no other comorbidities were 
detected. Since abnormality of the left adrenal gland was 
highly suspected to be metastatic lesion, the left adrenal-
ectomy was performed in October 2010.
HP analysis confirmed metastasis of breast cancer in 
the left adrenal gland tissue (Figure 1). IHC phenotype 
was CK7 +/-, CK 20 -, vimentin -, estrogen +, gross cystic 
disease fluid protein -15 (GCDFP-15) +/-, with ER score 
6 (4+2), 40% of tumor cells had middle staining intensity 
of nucleus (Figure 2), PR score 3 (2+1), 5% of tumor cells 
had poor staining intensity and HER2 was 2+, 20% of tu-
mor cells show complete membrane staining with middle 
intensity (Figure 3). Chromogenic in situ hybridization 
(CISH) analysis of HER2 gene amplification was positive. 
Marker of cell proliferation Ki-67 was high (50% of cells 
show immunoreactivity).
She started treatment with docetaxel plus trastuzum-
ab and after 6 cycles of docetaxel she continued therapy 
with trastuzumab alone with no evidence of disease. One 
year after left adrenalectomy was performed, abdominal 
CT scan showed enlargement of the right adrenal gland 
Figure 1. Histological section of adrenal metastatic disease (hema-
toxylin and eosin, 100×). Tumor cells arranged in solid nests infiltrating 
adrenal gland tissue.
Figure 3. Immuno-staining of adrenal metastatic disease, HER2 (IHC, 
200×). Tumor cells with HER2 2+ (20% of tumor cells show complete 
membrane staining with middle intensity).
Figure 2. Immuno-staining of adrenal metastatic disease, Estrogen re-
ceptors (IHC, 100×). Tumor cells with positivity for estrogen receptors, 
Allred score 6 (4+2) (40% of tumor cells had middle staining intensity 
of nucleus).
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with a diameter of 46×18 mm, and retroperitoneal poly-
lymphadenopathy, with the largest diameter of 27 mm. 
Adrenalectomy was not indicated due to the spread of the 
disease. She was treated with capecitabine (2000 mg/m2 for 
two weeks and one week of rest, every three weeks) for a 
period of one year with treatment effect of stable disease 
(SD). Unfortunately, afterwards she developed multiple 
brain metastases and underwent palliative radiotherapy of 
the brain lesions with a total dose of 30 Gy. She continued 
treatment with novel a nonsteroidal aromatase inhibitor 
anastrozole (1 mg per day) due to positive steroidal re-
ceptors in the left adrenal gland tissue, but she died three 
months later due to disease progression.
DISCUSSION
Adrenal gland metastases in most cases originate from 
lung cancer (35.4%), followed by gastric cancer (14.3%) 
and esophageal cancer (12.1%), while only in 2.9% of cases 
they originate from breast cancer, none of them with IDC 
findings on pathology examination [2, 10].
Adrenal gland metastases are almost always asymp-
tomatic and only in rare cases, if a large part of adrenal 
cortex is damaged by a tumor or both adrenal glands are 
affected, they can be associated with signs and symptoms 
of adrenal insufficiency. Netelenbos et al. [11] described 
in 2006 a clinical case of female breast cancer patient who 
developed adrenal insufficiency due to bilateral adrenal 
gland metastasis. After treatment for adrenal insufficiency 
she received 6 cycles of AC chemotherapy (doxorubicin 60 
mg/m2 day 1, cyclophosphamide 600 mg/m2 day 1, every 
three weeks) with the effect of partial regression confirmed 
by abdominal CT scan.
A recently published study of 3,726 patients and with 
a median follow-up of 14.8 years investigated patterns of 
breast cancer relapse and the metastatic sites based on 
breast cancer subtypes defined as luminal A, luminal B, 
luminal/HER2 positive, HER2-like and basal-like. This 
study showed that bones were the most common meta-
static site for all except for the basal-like subtype. How-
ever, HER2 subtype had a significantly higher incidence 
of spreading into brain, liver, bone and lungs, while metas-
tasis in other organs that originate from this subtype were 
much less frequent [12]. Other studies also suggested that 
distinct metastatic pathways may exist in breast cancer 
subtypes and that they could be driven by a set of specific 
biomarkers. As suggested by Paget’s seed and soil hypoth-
esis, the tumor-specific factors are complemented with the 
host microenvironments and their combination is crucial 
for the organotropism. Models of metastatic spread de-
scribe a complex interaction of factors involving tumor 
intravasation, circulation, extravasation, proliferation, 
angiogenesis and the microenvironment of the targeted 
tissues. Hence, the identification of tissue-specific signals 
involved in metastatic progression will open the way to 
new therapeutic strategies.
Our patient, with histology of IDC of the right breast, 
developed isolated metastasis in the left adrenal gland as 
the first site of disease relapse, three years after primary 
breast cancer was diagnosed. After having left adrenalec-
tomy HP analysis showed different IHC profile shifting 
from ER and PR negative in the primary breast cancer to 
ER and PR positive in adrenal metastases, while HER2 
status stayed positive both in primary cancer (HER2 3+) 
and in the adrenal metastases (CISH positive).
Several studies have reported discordance in up to 40% 
for hormone receptors and up to 20% for HER2 status 
between primary tumor and metastases [13, 14, 15]. It is 
unclear if these changes in receptor expression are a true 
biological phenomenon or may result from technical vari-
ables. Recent analysis using next generation sequencing 
technologies by Gerlinger et al. [16] performed on multi-
ple samples obtained from primary renal cell carcinomas 
and associated metastatic sites showed that no two samples 
were genetically identical. They reported that about two-
thirds of the mutations present in a single biopsy were 
not present in biopsies taken from across the same tumor. 
This and other data raise the possibility that presentation 
of a tumor molecular profile obtained from a single bi-
opsy sample may not be adequate for appropriate tumor 
treatment.
In a daily clinical reality discordant hormone recep-
tor status and HER2 status between the primary tumor 
and metastatic site might have important role in decisions 
making for future treatment. Improved understanding of 
metastatic spread pattern could possibly influence adju-
vant therapy and surveillance and could help to determine 
which therapies are suitable once distant disease has been 
diagnosed.
We would like to emphasize that our patient was 
treated according to the standard clinical protocol for the 
treatment of locally advanced breast cancer in 2007. The 
reason why IHC analysis of steroid receptors and HER2 
status in tumor samples obtained after radical mastec-
tomy was not done at that time was due to the limited 
resources and Institute’s recommendation that receptor 
status should be obtained either from the initial biopsy 
or after definite surgery. However, for the purpose of this 
manuscript and with intention to present the entire recep-
tor status profile over time we performed IHC analysis 
of steroid receptors and HER2 of the primary tumor af-
ter radical mastectomy and found the following receptor 
status: ER positive score 7 (4+3) 40% of the cells showed 
strong membrane staining; PR positive score 6 (3+3), 25% 
of the cells showed strong membrane staining; HER2 2+, 
20% of the cells showed moderate membrane staining, 
CISH positive; Ki-67 was 5%. Current treatment options 
and the availability of IHC analysis from the primary tu-
mor after mastectomy would likely have an impact on the 
course and outcome of our patient’s disease. However, the 
aim of this manuscript was to present this extremely rare 
metastatic site of IDC.
Nowadays, recommendations for the treatment of iso-
lated metastasis of breast cancer in adrenal glands are still 
missing. Studies investigating the treatment of isolated ad-
renal metastasis that originate from other cancers, such 
as lung, renal and colorectal cancer showed that adrenal-  
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ectomy increases survival in patients having disease-free 
interval (DFI – from the moment of diagnosed primary 
cancer until the appearance of isolated adrenal metasta-
sis) longer than 6 months [1, 17-20]. The abovementioned 
patient described by Liu et al. [8] lived three years after 
adrenalectomy without signs of the breast cancer disease. 
Understanding the pattern of relapse at a very early stage 
can help direct clinicians to appropriate and targeted 
therapies and may contribute to better overall survival by 
blocking or delaying the onset of metastases.
The isolated adrenal gland metastases from IDC of the 
breast are extremely rare, almost asymptomatic and so 
far only one clinical case was described and published. 
Hereby, we present our clinical case of isolated adrenal 
metastasis from IDC treated with adrenalectomy and post-
operative chemotherapy. Since such cases are very rare, 
treatment recommendations are not expected in the near 
future, however publications of individual clinical cases 
might be valuable in further clinical diagnosis, treatment 
and research of breast cancer patients.
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КРАТАК САДРЖАЈ
Увод Изо  ло  ва  не ме  та  ста  зе ин  ва  зив  ног дук  тал  ног кар  ци  но-
ма дој  ке у над  бу  бре  жној жле  зди су из  у  зет  но рет  ке. Пред  ста-
вља  мо слу  чај изо  ло  ва  не ме  та  ста  зе у ле  вој над  бу  бре  жној 
жле  зди от  кри  ве  не три го  ди  не од ди  јаг  но  зе при  мар  ног ту-
мо  ра дој  ке.
При  каз бо  ле  сни  ка Же  на ста  ра 58 го  ди  на за  по  че  ла је ле-
че  ње ло  кал  но од  ма  клог кар  ци  но  ма де  сне дој  ке, кли  нич  ког 
ста  ди  ју  ма IIIA (T2N2M0), нео  а  дју  вант  ном ан  тра  ци  клин  ском 
хе  ми  о  те  ра  пи  јом на  кон што је би  оп  си  јом по  твр  ђе  но да је реч 
о ин  ва  зив  ном дук  тал  ном кар  ци  но  му дој  ке. Иму  но  хи  сто  хе-
миј  ска ана  ли  за по  ка  за  ла је да је реч о ту  мо  ру с не  га  тив  ним 
сте  ро  ид  ним ре  цеп  то  ри  ма за естро  ген и про  ге  сте  рон, док је 
ре  цеп  тор ху  ма  ног епи  дер  мал  ног фак  то  ра ра  ста 2 (HER2) био 
по  зи  ти  ван. На  кон че  ти  ри ци  клу  са хе  ми  о  те  ра  пи  је и пар  ци-
јал  не ре  гре  си  је ту  мо  ра учи  ње  на је ра  ди  кал  на ма  стек  то  ми  ја 
де  сне дој  ке. Ко  нач  на па  то  хи  сто  ло  шка ана  ли  за по  твр  ди  ла је 
да је у пи  та  њу ин  ва  зив  ни дук  тал  ни кар  ци  ном дој  ке. Ле  че  ње 
је на  ста  вље  но адју  вант  ном хе  ми  о  те  ра  пи  јом до ку  му  ла  тив  не 
до  зе ан  тра  ци  кли  на, по  сто  пе  ра  ци  о  ном зрач  ном те  ра  пи  јом и 
адју  вант  ним тра  сту  зу  ма  бом. На  кон три го  ди  не од при  мар  не 
ди  јаг  но  зе ком  пју  те  ри  зо  ва  на то  мо  гра  фи  ја аб  до  ме  на от  кри-
ла је ту  мор у ле  вој над  бу  бре  жној жле  зди као је  ди  но ме  сто 
ме  та  ста  зе. Учи  ње  на је ле  ва адре  на  лек  то  ми  ја и па  то  хи  сто-
ло  шки је по  твр  ђе  на ме  та  ста  за кар  ци  но  ма дој  ке. Бо  ле  сни  ца 
је по  сле опе  ра  ци  је при  ми  ла шест ци  клу  са до  це  так  се  ла уз 
тра  сту  зу  маб, ко  ји је на  ста  вљен до про  гре  си  је бо  ле  сти. Го-
ди  ну да  на на  кон ле  ве адре  на  лек  то  ми  је кон  трол  ни ске  нер 
аб  до  ме  на от  крио је ту  мор у де  сном над  бу  бре  гу с ре  тро  пе-
ри  то  не  ал  ном лим  фа  де  но  па  ти  јом. Ле  че  ње је на  ста  вље  но 
ка  пе  ци  та  би  ном го  ди  ну да  на, на  кон че  га су от  кри  ве  не ме-
та  ста  зе мо  зга ко  је су узро  ко  ва  ле смрт  ни ис  ход.
За  кљу  чак Ра  ди што бо  љег раз  у  ме  ва  ња пу  те  ва ме  та  ста  зи  ра-
ња ин  ва  зив  ног дук  тал  ног кар  ци  но  ма дој  ке, би  ло би ве  о  ма 
ко  ри  сно пу  бли  ко  ва  ти све по  је  ди  нач  не слу  ча  је  ве с рет  ким 
об  ли  ци  ма ме  та  ста  зи  ра  ња. 
Кључ  не ре  чи: адре  на  лек  то  ми  ја; кар  ци  ном дој  ке; ин  ва  зив  ни 
дук  тал  ни кар  ци  ном; ме  та  ста  за
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